±¹³»µµ¼
Àü°øµµ¼/´ëÇб³Àç
ÀǾàÇа£È£°è¿
2013³â 9¿ù 9ÀÏ ÀÌÈÄ ´©Àû¼öÄ¡ÀÔ´Ï´Ù.
Á¤°¡ |
80,000¿ø |
---|
80,000¿ø
2,400P (3%Àû¸³)
ÇÒÀÎÇýÅÃ | |
---|---|
Àû¸³ÇýÅà |
|
|
|
Ãß°¡ÇýÅÃ |
|
À̺¥Æ®/±âȹÀü
¿¬°üµµ¼
»óÇ°±Ç
ÀÌ»óÇ°ÀÇ ºÐ·ù
Ã¥¼Ò°³
±¹³»¿¡¼´Â 2013³â¿¡ ´ëÇÑ°¡Àӷº¸Á¸ÇÐȸ(Korean Society for Fertility Preservation, KSFP)°¡ ⸳µÇ¸é¼ °¡Àӷº¸Á¸¿¡ ´ëÇÑ º»°ÝÀûÀÎ ³íÀÇ¿Í ¹ßÀüÀÌ °¡¼Ó鵃 ¼ö ÀÖ¾úÀ¸¸ç, ÀÌ´Â ¸¹Àº ȸ¿ø ¿©·¯ºÐµéÀÇ ¾Æ³¦¾ø´Â ¿Á¤°ú ¼º¿øÀÌ ÀÖ¾ú±â¿¡ °¡´ÉÇÏ¿´½À´Ï´Ù.
ÀÌ Ã¥Àº Áö±Ý±îÁöÀÇ °¡Àӷº¸Á¸ ºÐ¾ß ¹ßÀü¿¡ ¹ß¸ÂÃß¾î °¡Àӷº¸Á¸ÀÇ ¿ª»ç¿¡¼ºÎÅÍ ÃÖ½ÅÀÇ ¿¬±¸°á°úµé±îÁö ü°èÀûÀ¸·Î Á¤¸®ÇÏ¿© ±¹³» ÃÖÃÊÀÇ °¡Àӷº¸Á¸ ±³°ú¼·Î¼ ÀÌ ºÐ¾ß¸¦ °øºÎÇÏ°íÀÚ ÇÏ´Â ÀÇ°ú´ëÇлý, ¼ö·ÃÀǻӸ¸ ¾Æ´Ï¶ó °¡Àӷº¸Á¸ ȯÀÚ¸¦ ¸¸³ª´Â ¿©·¯ ÀÇ·á ÇöÀåÀÇ ÀÇ·áÀε鿡°Ô ´Ù°¢µµÀÇ Á¤º¸¿Í Àü¹® Áö½ÄÀ» Á¦°øÇÏ°íÀÚ ÇÏ¿´½À´Ï´Ù.
ù ´Ü¿ø¿¡¼´Â °¡Àӷº¸Á¸ÀÇ °³³äÀûÀÎ ³»¿ëÀ» ºñ·ÔÇÏ¿© µ¿°á»ý¹°ÇÐÀ» Æ÷ÇÔÇÏ´Â ±âÃÊÀûÀÎ ³»¿ëÀ» ü°èÀûÀ¸·Î ´Ù·ç¾ú°í, Ç×¾ÏÄ¡·á°¡ °¡Àӷ¿¡ ¹ÌÄ¡´Â ¿µÇâ»Ó¸¸ ¾Æ´Ï¶ó ¾ç¼º ÁúȯÀÌ °¡Àӷ¿¡ ¹ÌÄ¡´Â ¿µÇâ ¹× °¡Àӷº¸Á¸ÀÇ Á߿伺¿¡ ´ëÇؼµµ »ìÆ캸¾Ò½À´Ï´Ù. µÎ ¹ø° ´Ü¿ø¿¡¼´Â °¡Àӷº¸Á¸ Ä¡·áÀÇ ¹æ¹ý¿¡ ´ëÇÑ ÃÖ±Ù±îÁöÀÇ ¿¬±¸°á°úµéÀ» º»°ÝÀûÀ¸·Î ½Éµµ ÀÖ°Ô ´Ù·ç°í ³²¼ºÀÇ °¡Àӷº¸Á¸¿¡ ´ëÇؼµµ »ó¼¼È÷ ´Ù·ç¾ú½À´Ï´Ù. ¶ÇÇÑ, °¡Àӷº¸Á¸ ȯÀÚ¿¡ ´ëÇÑ ´ÙÇÐÁ¦Àû Á¢±ÙÀÇ Á߿伺°ú °ü·ÃÇÏ¿© °¡Àӷº¸Á¸ Ä¡·áÀÇ Á¦°ø°ú »ó´ã, °¡Àӷº¸Á¸ ÀÌÈÄÀÇ °ü¸®¿Í °èȹ, À±¸®ÀûÀÎ °í·Á µî¿¡ ´ëÇؼµµ Æø³Ð°Ô ´ã¾Ò½À´Ï´Ù. ¸¶Áö¸·À¸·Î´Â °¡±î¿î ¹Ì·¡¿¡ °¡Àӷº¸Á¸ Ä¡·áÀÇ È¹±âÀûÀÎ ¹ßÀüÀ» µµ¸ðÇÒ °ÍÀ¸·Î ±â´ëµÇ´Â Áٱ⼼Æ÷¿Í Àç»ýÀÇÇÐ µîÀ» ±â¹ÝÀ¸·Î ÇÑ ÃֽŠ¿¬±¸µé°ú Àü¹®°¡Àû Áö°ßÀ» ¼Ò°³ÇÏ¿´½À´Ï´Ù.
¸ñÂ÷
SECTION 1 °¡Àӷº¸Á¸ °³·Ð(Introduction)
CHAPTER 01 °¡Àӷº¸Á¸ÀÇ ¿ª»ç: º¸Á¶»ý½Ä¼ú·ÎºÎÅÍ °¡Àӷº¸Á¸±îÁö(History: from ART to fertility preservation)
1. º¸Á¶»ý½Ä¼úÀÇ ¿ª»ç
2. °¡Àӷº¸Á¸ÀÇ ¹ßÀü
3. ±¹³»/±¹¿Ü °¡Àӷº¸Á¸ °ü·Ã ÇÐȸ
References
CHAPTER 02 ¾ÏÄ¡·á¿Í °¡ÀÓ·Â(The effect of cancer therapy on reproductive function)
1. ¾ÏÄ¡·á¿Í °¡Àӷº¸Á¸ÀÇ Á߿伺
2. ¾ÏÄ¡·á°¡ °¡Àӷ¿¡ ¹ÌÄ¡´Â ¿µÇâ
3. °¢Á¾ ¾ÏÄ¡·á°¡ °¡Àӷ¿¡ ¹ÌÄ¡´Â ¿µÇâ
4. ¼Ò°á
References
CHAPTER 03 ¾ç¼º Áúȯ¿¡¼ÀÇ °¡Àӷº¸Á¸(Fertility preservation in non-cancer patients)
1. ³ªÀÌ¿Í °¡ÀÓ·Â
2. °¡Àӷº¸Á¸À» °í·ÁÇÒ ¼ö ÀÖ´Â ¾ç¼º Áúȯ
References
CHAPTER 04 °¡Àӷº¸Á¸À» À§ÇÑ ³¼Ò±â´É Æò°¡(Ovarian reserve test for fertility preservation)
1. ÀÌÇÐÀû ³»ºÐºñ °Ë»ç ¹× À¯¹ß°Ë»ç(Laboratory endocrine assessment and dynamic testing)
2. À¯¹ß°Ë»ç(Dynamic tests of ovarian reserve)
3. ÃÊÀ½ÆÄ ÁöÇ¥(Ultrasound parameters)
4. ³ªÀÌ(Age)
References
CHAPTER 05 µ¿°á»ý¹°ÇÐ(Cryobiology)
1. ¹°ÀÇ µ¿°á
2. µ¿°á¼Õ»ó(cryodamage) ±âÀü
3. ¿Ï¸¸µ¿°á
4. À¯¸®Èµ¿°á
5. µ¿°áº¸È£Á¦
6. µ¿°á-Çص¿ ÇÁ·Î±×·¥ÀÇ »ý½ÄÀÇÇÐºÐ¾ß Àû¿ë°ú °í·Á ¿äÀÎ
7. µ¿°á-Çص¿ ÇÁ·Î±×·¥ÀÇ ÀáÀçÀû À§Ç輺 °íÂû
References
SECTION 2 °¡Àӷº¸Á¸ Ä¡·á(Fertility Preservation Treatments)
CHAPTER 06 °¡Àӷº¸Á¸À» À§ÇÑ °ú¹è¶õÀ¯µµ(Ovarian stimulation protocol for fertility preservation)
1. ¼·Ð
2. ÀþÀº ¿©¼º À¯¹æ¾Ï ȯÀÚÀÇ À¯ÀüÇÐÀû, ÀÓ»óÀû ¾ç»ó
3. °¡Àӷº¸Á¸À» À§ÇÑ ³¼ÒÀÚ±Ø: ¡°Going beyond physiological standards¡±
4. °á·Ð
References
CHAPTER 07 ³ÀÚ¿Í ¹è¾Æ µ¿°áº¸Á¸(Cryopreservation of oocyte and embryo)
1. ¼·Ð(Introduction)
2. °¡Àӷº¸Á¸ Ä¡·áÀÇ ÀûÀÀÁõ(Candidates for fertility preservation)
3. ¹è¾Æ µ¿°áº¸Á¸(Embryo cryopreservation)
4. ³ÀÚ µ¿°áº¸Á¸(Oocyte cryopreservation)
5. ¼¼ºÎÀû °í·Á»çÇ×(Specific considerations)
6. °á·Ð(Conclusion)
References
CHAPTER 08 ³¼Ò Á¶Á÷ µ¿°áº¸Á¸°ú À̽Ä(Ovarian tissue cryopreservation and transplantation)
1. ³¼Ò Á¶Á÷ µ¿°á-Çص¿ ¹× ÀÌ½Ä ½Ã °¡À̵å¶óÀÎ
2. ³ÀÚ ¶Ç´Â ¹è¾Æ µ¿°á¹ý°úÀÇ Â÷ÀÌÁ¡
3. ³¼Ò Á¶Á÷ÀÇ È¹µæ, µ¿°á, ÀÌ½Ä ¹æ¹ý
4. ³¼Ò Á¶Á÷ µ¿°á-Çص¿ ¹× À̽İú °ü·ÃÇÏ¿© ÇØ°áÇØ¾ß ÇÒ °úÁ¦µé
5. Çѱ¹¿¡¼ÀÇ µ¿°á-Çص¿ ³¼Ò ÀÌ½Ä ¹× ü¿Ü¼öÁ¤ ½Ã¼ú·Ê
6. Àüü ³¼Ò µ¿°áº¸Á¸ ¹× À̽Ä(Whole ovary transplantation)
7. ¸ÎÀ½¸»
References
CHAPTER 09 ¹Ì¼º¼÷³ÀÚÀÇ Ã¼¿Ü¼º¼÷(In vitro maturation of immature oocyte)
1. °³¿ä ¹× ÀûÀÀÁõ
2. ¹Ì¼º¼÷³ÀÚ Ã¤Ãë ¹× Ã¼¿Ü¼º¼÷ °úÁ¤
3. IVM ±â¹ýÀÇ ¾ÈÀü¼º
4. °¡Àӷº¸Á¸ Ãø¸é¿¡¼ÀÇ ¹Ì¼º¼÷³ÀÚÀÇ ÀÌ¿ë
References
CHAPTER 10 »ý½Ä»ùÀÚ±ØÈ£¸£¸ó¹æÃâ È£¸£¸óÀÛ¿ëÁ¦(GnRH agonist)
1. °³¿ä
2. GnRHa°¡ ³¼Ò±â´ÉÀ» ¾î¶»°Ô º¸Á¸Çϴ°¡?
3. GnRHaÀÇ È¿°ú¿¡ ´ëÇÑ ±Ù°Å
4. °á·Ð
References
CHAPTER 11 °¡Àӷº¸Á¸¼ö¼ú(Fertility sparing surgery)
1. °³¿ä
2. ³¼Ò Á¶Á÷ µ¿°áº¸Á¸ ¼ö¼ú ¹× À̽Ä
3. ³¼Ò Á¶Á÷ äÃë ¹× ¼ö¼úµµ±¸
4. ³¼Ò Á¶Á÷ ÀÌ½Ä ½Ã ¼ö¼úÀû °í·Á»çÇ×
5. Àüü ³¼Ò µ¿°áº¸Á¸ ¹× À̽Ä(Whole ovary transplantation)
6. ³¼Ò Á¶Á÷ µ¿°áº¸Á¸ ¼ö¼ú ¹× À̽ļú ÈÄ ³¼Ò±â´Éȸº¹
7. ³¼Ò Á¶Á÷ µ¿°áº¸Á¸ ¼ö¼ú ¹× À̽ļú ÈÄ ÀӽŰá°ú
8. ºÎÀÎÁ¾¾ç ȯÀÚ¿¡ ´ëÇÑ °¡Àӷº¸Á¸ ¼ö¼ú
9. °á·Ð
References
CHAPTER 12 ³²¼º °¡Àӷº¸Á¸(Male fertility preservation)
1. ¼·Ð
2. ¾ÏÄ¡·á¿Í ³²¼º °¡ÀÓ·Â
3. ¾ÏÄ¡·á Àü ½ÃÇàÇϴ ȣ¸£¸ó¾ïÁ¦Ä¡·á(Hormone suppression before cancer therapy)
4. Á¤Àڳõ¿º¸Á¸(Cryopreservation of spermatozoa)
5. Á¤Á¶Áٱ⼼Æ÷¿Í »ý½Ä¼¼Æ÷ÀÇ ³Ãµ¿º¸Á¸ ¹× À̽Ä(Cryopreservation and transplantation of spermatogonial stem cell and germ cell)
6. °íȯÁ¶Á÷³Ãµ¿º¸Á¸ ¹× À̽Ä
7. °á·Ð
References
SECTION 3 °¡Àӷº¸Á¸ ȯÀÚÀÇ °ü¸®(Care of Fertility Preservation Patients)
CHAPTER 13 °¡Àӷº¸Á¸ Ä¡·áÀÇ Á¦°ø(Organization of fertility presercation care)
1. ¾ÏȯÀÚÀÇ °¡Àӷº¸Á¸ ÀÇ»ç°áÁ¤¿¡ ¾î·Á¿òÀ» ÁÖ´Â ¿ä¼Ò
2. ÇöÀç °¡Àӷº¸Á¸ ÇÁ·Î±×·¥ÀÇ ÇÑ°è
3. ¼º°øÀûÀÎ °¡Àӷº¸Á¸ ÇÁ·Î±×·¥À» À§ÇÑ ¹æ¹ý
4. ºÎÀξÏȯÀÚ¸¦ À§ÇÑ °¡Àӷº¸Á¸ÀÇ Æ¯º° °í·Á »çÇ×
References
CHAPTER 14 °¡Àӷº¸Á¸ ÈÄ ³ÀÓ Ä¡·á(Fertility treatment after fertility preservation)
1. °¡Àӷº¸Á¸ ÈÄ ³ÀÓ Ä¡·á ¼º°ø·ü
2. °á·Ð
References
CHAPTER 15 »ê°úÀû °á°ú ¹× °ü¸®(Obstetric outcomes and care)
1. ¾Ï »ýÁ¸ÀÚÀÇ Àӽſ¡ ¾ÏÀÌ ¹ÌÄ¡´Â ¿µÇâ(Effect of cancer on survivor¡¯s pregnancy)
2. ÇâÈÄ ÀӽŠ°á°ú¿¡ Ç×¾ÏÄ¡·á ¹× ¹æ»ç¼±Ä¡·á°¡ ¹ÌÄ¡´Â ¿µÇâ(Effect of chemotherapy and radiotherapy on future obstetric outcomes)
3. °¡Àӷº¸Á¸ Ä¡·áÀÇ ÀӽŠ°á°ú(Obstetric outcomes of fertility preservation treatment)
4. ¾Ï »ýÁ¸ÀÚ ÀӽŠ¹× °¡Àӷº¸Á¸ Ä¡·á ÈÄ ÀӽŠ½ÃÀÇ °ü¸®(Management of pregnancy in cancer survivor or pregnancy after fertility preservation treatment)
References
CHAPTER 16 °¡Àӷº¸Á¸ÀÇ À±¸®Àû °í·Á(Ethical considerations in fertility preservation)
1. ¾ÏȯÀÚÀÇ ¼±ÅÃ(Patient¡¯s dilemma: balancing cancer and fertility)
2. µ¿ÀǼ(Informed consent)
3. ¼ºÀο¡¼ÀÇ °¡Àӷº¸Á¸¼ú
4. ¼Ò¾Æ¿¡¼ÀÇ °¡Àӷº¸Á¸¼ú
5. ¾Ï Ä¡À¯ ÈÄ Ãâ»ê(Cancer surviviors¡¯ reproduce)
6. »çÈÄ µ¿°á ¼¼Æ÷/Á¶Á÷ÀÇ »ç¿ë(Posthumous use of stored reproductive tissue)
7. °á¾î
References
SECTION 4 °¡Àӷº¸Á¸ Ä¡·áÀÇ Àü¸Á(Future Techniques for Fertility Preservation)
CHAPTER 17 °¡Àӷº¸Á¸ Ä¡·áÁ¦(Fertoprotective agents)
1. Ammonium trichloro (dioxoethylene- o,o¡¯) tellurate ; AS101
2. Ceramide-1 Phosphates, C1P
3. Ç׹ķ¯°üÈ£¸£¸ó(Anti-mullerian hormaone, AMH)
4. mTOR inhibitors; ¿¡¹ö·Ñ¸®¹«½º(Everolimus)
5. À̸¶Æ¼´Õ(Imatinib)
6. ¸á¶óÅä´Ñ(Melatonin)
7. Ÿ¸ñ½ÃÆæ(Tamoxifen)
8. ±âŸ ¿¬±¸ ÁßÀÎ ¾à¹°
References
CHAPTER 18 ³¼Ò±â´ÉÀÇ Àç»ý(Ovarian rejuvenation)
1. ¼·Ð
2. ³¼Ò Àç»ý Ä¡·á ÀÓ»ó ¿¬±¸
3. Àü¸Á
References
CHAPTER 19 Àΰø³¼Ò¿Í »ý½Ä¼¼Æ÷ »ý¼º(Artificial ovary and stem cell technology for germ cell formation)
1. ¿©¼º °¡Àӷº¸Á¸À» À§ÇÑ Àΰø³¼Ò(Artificial ovary for female fertility preservation)
2. Áٱ⼼Æ÷ À¯·¡ »ý½Ä¼¼Æ÷ÀÇ »ý»ê(Production of germ cells from stem cells)
References
Index
º»¹®Áß¿¡¼
[¼¹®]
ü¿Ü¼öÁ¤½Ã¼ú(IVF-ET)À̶ó´Â ¹æ¹ýÀ» ÅëÇØ ¼º°øÀûÀ¸·Î »ý¸íÀ» ź»ý½ÃŲ 1978³âÀÇ ¿ª»çÀûÀΠù ¹ß°ÉÀ½À» ½ÃÀÛÀ¸·Î º¸Á¶»ý½Ä¼ú(ART)Àº ÇöÀç±îÁö ¾à 40¿© ³â°£ ´«ºÎ½Å ¹ßÀüÀ» °ÅµìÇØ¿Ô½À´Ï´Ù. ü¿Ü¼öÁ¤ ½Ã¼úÀº ³ÀÓ ºÎºÎµé¿¡°Ô ¸¹Àº Èñ¸ÁÀ» ÁÖ¾ú°í, ÀÌ´Â »ý½Ä³»ºÐºñÇÐ ¹ßÀüÀÇ ±ÍÁßÇÑ ¼º°ú¶ó°í ÇÒ ¼ö ÀÖÀ» °ÍÀÔ´Ï´Ù. ³ª¾Æ°¡ ÀÌÁ¦ º¸Á¶»ý½Ä¼úÀÇ ¹ßÀüÀº ³ÀÓ ºÎºÎµéÀÇ ÀӽŠ½Ãµµ»Ó¸¸ ¾Æ´Ï¶ó °¡Àӷº¸Á¸(Fertility Preservation, FP)ÀÇ ¿µ¿ªÀ¸·Î Àû¿ë ¹üÀ§°¡ È®ÀåµÇ¾ú°í, Ç×¾ÏÄ¡·á µîÀ¸·Î °¡ÀÓ·ÂÀÌ ÀúÇ쵃 ¼ö ÀÖ´Â »óȲ¿¡ óÇÑ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ °¡Àӷº¸Á¸ Ä¡·á°¡ ÇʼöÀûÀÎ ÀÇ·á ºÐ¾ß·Î ÀÚ¸® Àâ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ Áö¼ÓÀûÀ¸·Î °áÈ¥ ¿¬·ÉÀÌ ³ô¾ÆÁö°í ÀÌ¿¡ µû¶ó ¿©¼ºÀÇ Ãâ»ê ³ªÀÌ°¡ ³ô¾ÆÁö¸é¼ °¡Àӷº¸Á¸¿¡ ´ëÇÑ »çȸÀû °ü½Éµµ Å©°Ô Áõ°¡ÇÏ¿´½À´Ï´Ù. ¹«¾ùº¸´Ù ÀÌ¿Í °°Àº °¡Àӷº¸Á¸ ºÐ¾ßÀÇ ¹ßÀüÀº ±âÃÊ¿Í ÀÓ»óÀ» ¾Æ¿ì¸£´Â ¿©·¯ ¿¬±¸ÀÚµéÀÇ ³ë·Â°ú Çå½Å¿¡ ´õºÒ¾î À¯°ü ÇÐȸµéÀÇ È°¹ßÇÑ ÇмúÈ°µ¿°ú ±³·ù°¡ Å« ¿øµ¿·ÂÀÌ µÇ¾ú½À´Ï´Ù. ƯÈ÷ ±¹³»¿¡¼´Â 2013³â¿¡ ´ëÇÑ°¡Àӷº¸Á¸ÇÐȸ(Korean Society for Fertility Preservation, KSFP)°¡ ⸳µÇ¸é¼ °¡Àӷº¸Á¸¿¡ ´ëÇÑ º»°ÝÀûÀÎ ³íÀÇ¿Í ¹ßÀüÀÌ °¡¼Ó鵃 ¼ö ÀÖ¾úÀ¸¸ç, ÀÌ´Â ¸¹Àº ȸ¿ø ¿©·¯ºÐµéÀÇ ¾Æ³¦¾ø´Â ¿Á¤°ú ¼º¿øÀÌ ÀÖ¾ú±â¿¡ °¡´ÉÇÏ¿´½À´Ï´Ù.
ÀÌ Ã¥Àº Áö±Ý±îÁöÀÇ °¡Àӷº¸Á¸ ºÐ¾ß ¹ßÀü¿¡ ¹ß¸ÂÃß¾î °¡Àӷº¸Á¸ÀÇ ¿ª»ç¿¡¼ºÎÅÍ ÃÖ½ÅÀÇ ¿¬±¸°á°úµé±îÁö ü°èÀûÀ¸·Î Á¤¸®ÇÏ¿© ±¹³» ÃÖÃÊÀÇ °¡Àӷº¸Á¸ ±³°ú¼·Î¼ ÀÌ ºÐ¾ß¸¦ °øºÎÇÏ°íÀÚ ÇÏ´Â ÀÇ°ú´ëÇлý, ¼ö·ÃÀǻӸ¸ ¾Æ´Ï¶ó °¡Àӷº¸Á¸ ȯÀÚ¸¦ ¸¸³ª´Â ¿©·¯ ÀÇ·á ÇöÀåÀÇ ÀÇ·áÀε鿡°Ô ´Ù°¢µµÀÇ Á¤º¸¿Í Àü¹® Áö½ÄÀ» Á¦°øÇÏ°íÀÚ ÇÏ¿´½À´Ï´Ù.
ù ´Ü¿ø¿¡¼´Â °¡Àӷº¸Á¸ÀÇ °³³äÀûÀÎ ³»¿ëÀ» ºñ·ÔÇÏ¿© µ¿°á»ý¹°ÇÐÀ» Æ÷ÇÔÇÏ´Â ±âÃÊÀûÀÎ ³»¿ëÀ» ü°èÀûÀ¸·Î ´Ù·ç¾ú°í, Ç×¾ÏÄ¡·á°¡ °¡Àӷ¿¡ ¹ÌÄ¡´Â ¿µÇâ»Ó¸¸ ¾Æ´Ï¶ó ¾ç¼º ÁúȯÀÌ °¡Àӷ¿¡ ¹ÌÄ¡´Â ¿µÇâ ¹× °¡Àӷº¸Á¸ÀÇ Á߿伺¿¡ ´ëÇؼµµ »ìÆ캸¾Ò½À´Ï´Ù. µÎ ¹ø° ´Ü¿ø¿¡¼´Â °¡Àӷº¸Á¸ Ä¡·áÀÇ ¹æ¹ý¿¡ ´ëÇÑ ÃÖ±Ù±îÁöÀÇ ¿¬±¸°á°úµéÀ» º»°ÝÀûÀ¸·Î ½Éµµ ÀÖ°Ô ´Ù·ç°í ³²¼ºÀÇ °¡Àӷº¸Á¸¿¡ ´ëÇؼµµ »ó¼¼È÷ ´Ù·ç¾ú½À´Ï´Ù. ¶ÇÇÑ, °¡Àӷº¸Á¸ ȯÀÚ¿¡ ´ëÇÑ ´ÙÇÐÁ¦Àû Á¢±ÙÀÇ Á߿伺°ú °ü·ÃÇÏ¿© °¡Àӷº¸Á¸ Ä¡·áÀÇ Á¦°ø°ú »ó´ã, °¡Àӷº¸Á¸ ÀÌÈÄÀÇ °ü¸®¿Í °èȹ, À±¸®ÀûÀÎ °í·Á µî¿¡ ´ëÇؼµµ Æø³Ð°Ô ´ã¾Ò½À´Ï´Ù. ¸¶Áö¸·À¸·Î´Â °¡±î¿î ¹Ì·¡¿¡ °¡Àӷº¸Á¸ Ä¡·áÀÇ È¹±âÀûÀÎ ¹ßÀüÀ» µµ¸ðÇÒ °ÍÀ¸·Î ±â´ëµÇ´Â Áٱ⼼Æ÷¿Í Àç»ýÀÇÇÐ µîÀ» ±â¹ÝÀ¸·Î ÇÑ ÃֽŠ¿¬±¸µé°ú Àü¹®°¡Àû Áö°ßÀ» ¼Ò°³ÇÏ¿´½À´Ï´Ù.
ÇÊÀÚ´Â Áö³ 30¿© ³â°£ »êºÎÀΰú »ý½Ä³»ºÐºñÇп¡ ¸ö´ã¾Æ ±³À°, ¿¬±¸, Áø·á¿¡ Èû½á¿ÔÀ¸³ª °¡Àӷº¸Á¸¿¡ ´ëÇØ ÀÚ¼¼È÷ ¼³¸íµÇ¾î ÀÖ´Â ±¹¹® ±³°ú¼°¡ ºÎÁ·ÇÑ °ÍÀ» ´Ã ¾Æ½±°Ô »ý°¢ÇØ¿Ô½À´Ï´Ù. ÀÌ´Â ºñ´Ü ÇÊÀÚ»Ó¸¸ ¾Æ´Ï¶ó »ý½Ä³»ºÐºñÇÐÀ» Àü°øÇÏ´Â ´Ù¸¥ ÇöÁ÷ ÀÇ·áÁøµéÀÇ °øÅëµÈ °¥ÁõÀ̾ú°í, ÀÌ¿Í °ü·ÃÇÏ¿© Àß Á¤¸®µÈ ü°èÀûÀÎ Áö½ÄÀ» ÈÄÇп¡°Ô Àü´ÞÇÏ´Â ¹æ¹ýÀ» ã¾Æº¸°íÀÚ ÇÏ´Â °ÍÀÌ ¿ì¸®ÀÇ °øÅëµÈ ÀÇ°ßÀ̾ú½À´Ï´Ù. ÀÇÁö°¡ ¸ðÀÎ »óȲ¿¡ ±âȸ±îÁö ´ê¾Æ ¿©·¯ Àü¹®°¡ ¼±»ý´Ôµé°ú °¡Àӷº¸Á¸ ±³°ú¼ ÃÊÆÇÀ» ÁýÇÊÇÏ°í Ãâ°£ÇÒ ¼ö ÀÖ°Ô µÇ¾î ÀÌ·ç ´Ù ¸»ÇÒ ¼ö ¾øÀÌ ±â»Ú°í ¹÷Âù ¸¶À½ÀÔ´Ï´Ù. °³ÀÎÀûÀ¸·Î´Â Á¤³â ÁîÀ½ÇÏ¿© ¼÷¿øÇÑ ¹Ù¸¦ ¸¶¹«¸®ÇÒ ¼ö ÀÖ°Ô µÇ¾î ÇâÈÄ Áø·á ¹× ¿¬±¸
¿¡ Á¶±ÝÀÌ¶óµµ µµ¿òÀ» ÁÙ ¼ö ÀÖÀ» °ÍÀ̶ó´Â ±â´ë¿Í À§¾ÈÀ» °¡Áö°í Á¤µç °ø°£À» ¶°³¯ ¼ö ÀÖ¾î ³Ê¹«³ª °¨»çÇÑ ¸¶À½ÀÔ´Ï´Ù. ¹«¾ùº¸´Ù ÀÌ Ã¥À» ÃâÆÇÇϱâ±îÁö ¼ö°í¿Í ³ë·ÂÀ» ¾Æ³¢Áö ¾Ê¾Æ ÁֽŠ¸¹Àº ºÐµé²² Áø½ÉÀ¸·Î °¨»çÀÇ Àλ縦 µå¸³´Ï´Ù. ±¹³» °¡Àӷº¸Á¸ ¿¬±¸¿Í Áø·áÀÇ ÃÖ°í Àü¹®°¡µéÀÌ ÁýÇÊ¿¡ Âü¿©ÇÏ¿©, ¾ËÂ÷°í À¯ÀÍÇÑ ³»¿ëÀÇ ±³°ú¼°¡ µÉ ¼ö ÀÖµµ·Ï ÃÖ¼±À» ´ÙÇØ ÁýÇÊÇØ Áּ̽À´Ï´Ù. ¹Ù»Ú½Å ¿ÍÁß¿¡µµ ÈçÄèÈ÷ ÁýÇÊÀ» ¸Ã¾ÆÁØ ÀúÀÚµé, °ËÅä¿¡ Âü¿©ÇØ ÁÖ½Ã°í ±âȹ°ú ÆíÁýÀ» ¸Ã¾Æ ÁֽŠÃâÆÇ»ç Á÷¿ø ¿©·¯ºÐµé²² ±íÀº °¨»çÀÇ ¸»¾¸ ¿Ã¸³´Ï´Ù.
ÀÌ Ã¥ÀÌ °¡Àӷº¸Á¸À» °øºÎÇÏ°íÀÚ ÇÏ´Â ÈÄÇеé°ú, °¡Àӷº¸Á¸ Ä¡·á°¡ ÇÊ¿äÇÑ È¯Àڵ鿡°Ô ÃÖ¼±ÀÇ Áø·á¸¦ Çϱâ À§ÇØ ¹ã³·¾øÀÌ °í¹ÎÇÏ°í ¿¬±¸ÇÏ´Â ¸¹Àº ÀÇ·áÁøµé¿¡°Ô ¾ÆÁÖ Á¶±ÝÀ̳ª¸¶ µµ¿òÀÌ µÉ ¼ö Àֱ⸦ ¹Ù¶ø´Ï´Ù. ±×¸®°í º» ÃâÆÇÀ» Ãʼ®À¸·Î ÇÏ¿© ´õ¿í ¾ËÂù ³»¿ëÀ¸·Î °Åµì °³Á¤ÆÇÀÌ Ãâ°£µÇ¾î °¡Àӷº¸Á¸ Çй® ¹ßÀüÀÇ ¹ßÆÇÀÌ µÉ ¼ö Àֱ⸦ ±â´ëÇÕ´Ï´Ù.
2021³â 7¿ù
´ëÇ¥ÀúÀÚ
¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ »êºÎÀΰúÇб³½Ç ±³¼ö
±è ¼® Çö
ÀúÀÚ¼Ò°³
»ý³â¿ùÀÏ | - |
---|
ÇØ´çÀÛ°¡¿¡ ´ëÇÑ ¼Ò°³°¡ ¾ø½À´Ï´Ù.
»ý³â¿ùÀÏ | - |
---|
ÇØ´çÀÛ°¡¿¡ ´ëÇÑ ¼Ò°³°¡ ¾ø½À´Ï´Ù.
ÁÖ°£·©Å·
´õº¸±â»óÇ°Á¤º¸Á¦°ø°í½Ã
À̺¥Æ® ±âȹÀü
Àü°øµµ¼/´ëÇб³Àç ºÐ¾ß¿¡¼ ¸¹Àº ȸ¿øÀÌ ±¸¸ÅÇÑ Ã¥
ÆǸÅÀÚÁ¤º¸
»óÈ£ |
(ÁÖ)±³º¸¹®°í |
---|---|
´ëÇ¥ÀÚ¸í |
¾Èº´Çö |
»ç¾÷ÀÚµî·Ï¹øÈ£ |
102-81-11670 |
¿¬¶ôó |
1544-1900 |
ÀüÀÚ¿ìÆíÁÖ¼Ò |
callcenter@kyobobook.co.kr |
Åë½ÅÆǸž÷½Å°í¹øÈ£ |
01-0653 |
¿µ¾÷¼ÒÀçÁö |
¼¿ïƯº°½Ã Á¾·Î±¸ Á¾·Î 1(Á¾·Î1°¡,±³º¸ºôµù) |
±³È¯/ȯºÒ
¹ÝÇ°/±³È¯ ¹æ¹ý |
¡®¸¶ÀÌÆäÀÌÁö > Ãë¼Ò/¹ÝÇ°/±³È¯/ȯºÒ¡¯ ¿¡¼ ½Åû ¶Ç´Â 1:1 ¹®ÀÇ °Ô½ÃÆÇ ¹× °í°´¼¾ÅÍ(1577-2555)¿¡¼ ½Åû °¡´É |
---|---|
¹ÝÇ°/±³È¯°¡´É ±â°£ |
º¯½É ¹ÝÇ°ÀÇ °æ¿ì Ãâ°í¿Ï·á ÈÄ 6ÀÏ(¿µ¾÷ÀÏ ±âÁØ) À̳»±îÁö¸¸ °¡´É |
¹ÝÇ°/±³È¯ ºñ¿ë |
º¯½É ȤÀº ±¸¸ÅÂø¿À·Î ÀÎÇÑ ¹ÝÇ°/±³È¯Àº ¹Ý¼Û·á °í°´ ºÎ´ã |
¹ÝÇ°/±³È¯ ºÒ°¡ »çÀ¯ |
·¼ÒºñÀÚÀÇ Ã¥ÀÓ ÀÖ´Â »çÀ¯·Î »óÇ° µîÀÌ ¼Õ½Ç ¶Ç´Â ÈÑ¼ÕµÈ °æ¿ì ·¼ÒºñÀÚÀÇ »ç¿ë, Æ÷Àå °³ºÀ¿¡ ÀÇÇØ »óÇ° µîÀÇ °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì ·º¹Á¦°¡ °¡´ÉÇÑ »óÇ° µîÀÇ Æ÷ÀåÀ» ÈѼÕÇÑ °æ¿ì ·½Ã°£ÀÇ °æ°ú¿¡ ÀÇÇØ ÀçÆǸŰ¡ °ï¶õÇÑ Á¤µµ·Î °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì ·ÀüÀÚ»ó°Å·¡ µî¿¡¼ÀÇ ¼ÒºñÀÚº¸È£¿¡ °üÇÑ ¹ý·üÀÌ Á¤ÇÏ´Â ¼ÒºñÀÚ Ã»¾àöȸ Á¦ÇÑ ³»¿ë¿¡ ÇØ´çµÇ´Â °æ¿ì |
»óÇ° Ç°Àý |
°ø±Þ»ç(ÃâÆÇ»ç) Àç°í »çÁ¤¿¡ ÀÇÇØ Ç°Àý/Áö¿¬µÉ ¼ö ÀÖÀ½ |
¼ÒºñÀÚ ÇÇÇغ¸»ó |
·»óÇ°ÀÇ ºÒ·®¿¡ ÀÇÇÑ ±³È¯, A/S, ȯºÒ, Ç°Áúº¸Áõ ¹× ÇÇÇغ¸»ó µî¿¡ °üÇÑ »çÇ×Àº¼ÒºñÀÚºÐÀïÇØ°á ±âÁØ (°øÁ¤°Å·¡À§¿øȸ °í½Ã)¿¡ ÁØÇÏ¿© ó¸®µÊ ·´ë±Ý ȯºÒ ¹× ȯºÒÁö¿¬¿¡ µû¸¥ ¹è»ó±Ý Áö±Þ Á¶°Ç, ÀýÂ÷ µîÀº ÀüÀÚ»ó°Å·¡ µî¿¡¼ÀǼҺñÀÚ º¸È£¿¡ °üÇÑ ¹ý·ü¿¡ µû¶ó ó¸®ÇÔ |
(ÁÖ)ÀÎÅÍÆÄÅ©Ä¿¸Ó½º´Â ȸ¿ø´ÔµéÀÇ ¾ÈÀü°Å·¡¸¦ À§ÇØ ±¸¸Å±Ý¾×, °áÁ¦¼ö´Ü¿¡ »ó°ü¾øÀÌ (ÁÖ)ÀÎÅÍÆÄÅ©Ä¿¸Ó½º¸¦ ÅëÇÑ ¸ðµç °Å·¡¿¡ ´ëÇÏ¿©
(ÁÖ)KGÀ̴Ͻýº°¡ Á¦°øÇÏ´Â ±¸¸Å¾ÈÀü¼ºñ½º¸¦ Àû¿ëÇÏ°í ÀÖ½À´Ï´Ù.
¹è¼Û¾È³»
±³º¸¹®°í »óÇ°Àº Åùè·Î ¹è¼ÛµÇ¸ç, Ãâ°í¿Ï·á 1~2Àϳ» »óÇ°À» ¹Þ¾Æ º¸½Ç ¼ö ÀÖ½À´Ï´Ù.
Ãâ°í°¡´É ½Ã°£ÀÌ ¼·Î ´Ù¸¥ »óÇ°À» ÇÔ²² ÁÖ¹®ÇÒ °æ¿ì Ãâ°í°¡´É ½Ã°£ÀÌ °¡Àå ±ä »óÇ°À» ±âÁØÀ¸·Î ¹è¼ÛµË´Ï´Ù.
±ººÎ´ë, ±³µµ¼Ò µî ƯÁ¤±â°üÀº ¿ìü±¹ Åù踸 ¹è¼Û°¡´ÉÇÕ´Ï´Ù.
¹è¼Ûºñ´Â ¾÷ü ¹è¼Ûºñ Á¤Ã¥¿¡ µû¸¨´Ï´Ù.